North America HbA1c Testing Market

North America HbA1c Testing Market Size (2024 to 2029)

The size of the North American HbA1c Testing market is anticipated to grow at 9.88% CAGR from 2024 to 2029 and be worth USD 1082 Million by 2029 from USD 676.1 Million in 2024.

Hemoglobin A1C (HbA1c) is a glucose-binding form of hemoglobin, and the HbA1c test gives the patient the average blood sugar level for the previous two to three months. For the best results, these tests are usually coupled with others.

One of the major factors likely to accelerate the growth of the North American HbA1c testing market is the increase in the number of diabetes research organizations and associations. Furthermore, over the forecast period, an increase in key player initiatives and the prevalence of diabetes are likely to contribute to the North American market's growth. The market's expansion is further expected to be fueled by the rising per capita disposable income and the development of healthcare infrastructure. In addition, the introduction of innovative treatment alternatives is moving the market forward.The rapid growth of medical tourism and the rise in demand for precise HbA1c level measurements are also expected to boost the market's growth. Furthermore, the increase in the senior population and the impact of a sedentary lifestyle and an unhealthy diet are predicted to fuel the expansion of the HbA1c testing market in North America.However, high costs associated with the testing equipment are predicted to hamper the market's growth rate. In addition, the restricted indications of HbA1c tests and strict reimbursement policies in developing countries are likely to restrain the expansion of the HbA1c testing market. The rise in accuracy concerns among the population may further limit the market's growth. The HbA1c standard range testing result may be erroneous due to inconsistencies in interpretations, impeding the expansion of the HbA1c assay market.

This research report on the North American HbA1c testing market has been segmented and sub-segmented into the following categories.

North America HbA1c Testing Market - By Technology

• Ion-Exchange HPCL             
• Enzymatic Assay   
• Affinity Binding Chromatography  
• Turbidimetric Inhibition Immunoassay       
• Other       

North America HbA1c Testing Market - By Type

• Hand-Held Devices               
• Bench Top Devices   

North America HbA1c Testing Market - By End User

• Hospital    
• Home Care              
• Diagnostic laboratory          
• Research Institutions

North America HbA1c Testing Market - By Country

• The United States
• Canada
• Rest of North America

As of 2023, North America accounted for the largest share of the HbA1c Testing market due to heavy expenditure on health care in developed nations such as the U.S. and Canada. The HbA1c testing market in North America also benefits from the introduction of point-of-care and other recent technologies that reduce diabetes testing costs. Diabetes patients are on the rise across North America as the aging population continues to grow. In addition, the market for HbA1c testing equipment is being boosted by the growing scope of medical tourism in underdeveloped countries.

The U.S. HbA1C testing market is predicted to lead the North American market during the forecast period.

The HbA1c market in the United States is expected to be favored by the increased usage of improved diagnostic tools and technologies and strategic initiatives such as collaborations and agreements by the key market players.

KEY MARKET PLAYERS

Companies playing a notable role in the North American HbA1c Testing market profiled in this report are Transasia Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, and Trinity Biotech plc.